CCEL Overview

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Wall Street analysts forecast CCEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCEL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cryo-Cell International Inc revenue for the last quarter amounts to 7.84M USD, decreased -2.26

Cryo-Cell International Inc. EPS for the last quarter amounts to -0.47 USD, increased 104.35

Cryo-Cell International Inc (CCEL) has 72 emplpoyees as of March 22 2026.

Today CCEL has the market capitalization of 25.13M USD.